Drug Trial Radar · NCT07908147
Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Mar 2027
Primary completion
Mar 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- Olivia Newton-John Cancer Research InstituteAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Fore Biotherapeutics; Akesobio Australia Pty Ltd
- First posted
- Oct 30, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- Single (investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will investigate whether rapid molecular testing of recurrent glioblastoma (GBM) can identify tumour biomarkers that may help guide treatment selection in younger people with IDH-wildtype GBM. Participants will be people under 55 years of age whose diagnosis is consistent with glioblastoma and who have undergone recent surgery or previously participated in the initial phase of the BRAid GBM study. Tumour tissue will undergo rapid molecular testing to identify biomarkers that may predict response to specific targeted treatments. Treatment decisions will be informed by the molecular characteristics of each participant's tumour and available evidence for treatments associated with the identified biomarkers. The study will assess the feasibility and safety of implementing rapid molecular testing across multiple Australian hospitals and whether this approach can provide timely information to support personalised treatment decisions. The study will also explore whether biomarker-guided treatment may provide alternatives to, or reduce the use of, radiotherapy in younger people with glioblastoma, with the potential to reduce long-term treatment-related effects on cognition and quality of life. Approximately 110 patients will be screened and 12 participants will be recruited from participating hospitals across Australia.
Conditions
- IDH Wildtype Glioblastoma
- Glioblastoma (GBM)
Interventions
LarotrectinibDrug
Larotrectinib is a first-in-class, highly selective, oral inhibitor of the tropomyosin receptor kinase (TRK) family of proteins (TRKA, TRKB and TRKC).
CadonilimabDrug
AK104 is bispecific IgG single chain Fv fragment (ScFv) monoclonal antibody that binds to human programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)
PlixorafenibDrug
Plixorafenib is a next generation, orally available, small-molecule, selective inhibitor of Class 1 and 2 mutated BRAF.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Feasibility of Rapid Molecular Profiling and Matched Targeted TherapyTime frame: From enrollment to initiation of chemoradiation (pre-treatment period).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Austin Hospital
Heidelberg, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.